Laura Scaltriti

1.2k total citations
10 papers, 456 citations indexed

About

Laura Scaltriti is a scholar working on Oncology, Surgery and Reproductive Medicine. According to data from OpenAlex, Laura Scaltriti has authored 10 papers receiving a total of 456 indexed citations (citations by other indexed papers that have themselves been cited), including 8 papers in Oncology, 3 papers in Surgery and 3 papers in Reproductive Medicine. Recurrent topics in Laura Scaltriti's work include Cancer Treatment and Pharmacology (5 papers), HER2/EGFR in Cancer Research (3 papers) and Ovarian cancer diagnosis and treatment (3 papers). Laura Scaltriti is often cited by papers focused on Cancer Treatment and Pharmacology (5 papers), HER2/EGFR in Cancer Research (3 papers) and Ovarian cancer diagnosis and treatment (3 papers). Laura Scaltriti collaborates with scholars based in Italy and United States. Laura Scaltriti's co-authors include Sandro Pignata, Enrico Breda, Domenico Priolo, Domenica Lorusso, Antonella Savarese, Gabriella Ferrandina, Pietro Del Medico, Giovanni Scambia, Dionyssios Katsaros and M. Ludovisi and has published in prestigious journals such as Journal of Clinical Oncology, Breast Cancer Research and Treatment and Critical Reviews in Oncology/Hematology.

In The Last Decade

Laura Scaltriti

10 papers receiving 444 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Laura Scaltriti Italy 8 225 176 128 79 77 10 456
Radosław Mądry Poland 16 513 2.3× 377 2.1× 49 0.4× 221 2.8× 48 0.6× 85 814
N. H. Cho South Korea 7 297 1.3× 62 0.4× 46 0.4× 271 3.4× 27 0.4× 10 647
Janine Lombard Australia 11 204 0.9× 89 0.5× 26 0.2× 88 1.1× 64 0.8× 38 395
Venkateshwari Ananthapur India 15 92 0.4× 73 0.4× 98 0.8× 154 1.9× 32 0.4× 73 547
Katsuya Matsuda Japan 12 92 0.4× 66 0.4× 57 0.4× 105 1.3× 39 0.5× 45 406
Giulia Pomati Italy 12 148 0.7× 63 0.4× 105 0.8× 51 0.6× 63 0.8× 27 392
Ghada E. Esheba Egypt 9 54 0.2× 66 0.4× 115 0.9× 73 0.9× 86 1.1× 19 277
Ursula Denison Austria 12 185 0.8× 295 1.7× 50 0.4× 69 0.9× 26 0.3× 30 687
Y. Torii Japan 13 74 0.3× 97 0.6× 49 0.4× 120 1.5× 27 0.4× 36 412
Louisa Mezache United States 10 189 0.8× 19 0.1× 76 0.6× 132 1.7× 26 0.3× 18 438

Countries citing papers authored by Laura Scaltriti

Since Specialization
Citations

This map shows the geographic impact of Laura Scaltriti's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Laura Scaltriti with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Laura Scaltriti more than expected).

Fields of papers citing papers by Laura Scaltriti

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Laura Scaltriti. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Laura Scaltriti. The network helps show where Laura Scaltriti may publish in the future.

Co-authorship network of co-authors of Laura Scaltriti

This figure shows the co-authorship network connecting the top 25 collaborators of Laura Scaltriti. A scholar is included among the top collaborators of Laura Scaltriti based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Laura Scaltriti. Laura Scaltriti is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

10 of 10 papers shown
1.
Gennari, Alessandra, Flavia Foca, Rita Zamarchi, et al.. (2020). Insulin-like growth factor-1 receptor (IGF-1R) expression on circulating tumor cells (CTCs) and metastatic breast cancer outcome: results from the TransMYME trial. Breast Cancer Research and Treatment. 181(1). 61–68. 19 indexed citations
2.
Cazzaniga, Marina Elena, Laura Cortesi, Laura Scaltriti, et al.. (2017). Metronomic Chemotherapy in Triple-Negative Metastatic Breast Cancer: The Future Is Now?. International Journal of Breast Cancer. 2017. 1–6. 12 indexed citations
3.
Cazzaniga, Marina Elena, Laura Cortesi, Laura Scaltriti, et al.. (2016). Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study. Breast Cancer Research and Treatment. 160(3). 501–509. 43 indexed citations
4.
Razzini, Giorgia, Muriel Assunta Musti, Elisa Stivanello, et al.. (2016). Acupuncture As an Integrative Approach for the Treatment of Hot Flashes in Women With Breast Cancer: A Prospective Multicenter Randomized Controlled Trial (AcCliMaT). Journal of Clinical Oncology. 34(15). 1795–1802. 84 indexed citations
5.
Mustacchi, Giorgio, Laura Biganzoli, P. Pronzato, et al.. (2015). HER2-positive metastatic breast cancer: A changing scenario. Critical Reviews in Oncology/Hematology. 95(1). 78–87. 24 indexed citations
6.
Giovanardi, Filippo, et al.. (2013). Increased Mean Corpuscular Volume of Red Blood Cells in Patients Treated with Capecitabine for Advanced Breast and Colon Cancer. Chemotherapy. 59(5). 369–372. 4 indexed citations
7.
Pisano, Carmela, Alessandro Morabito, Roberto Sorio, et al.. (2009). A phase II study of capecitabine in the treatment of ovarian cancer resistant or refractory to platinum therapy: a multicentre Italian trial in ovarian cancer (MITO-6) trial. Cancer Chemotherapy and Pharmacology. 64(5). 1021–1027. 7 indexed citations
8.
Ferrandina, Gabriella, M. Ludovisi, Domenica Lorusso, et al.. (2008). Phase III Trial of Gemcitabine Compared With Pegylated Liposomal Doxorubicin in Progressive or Recurrent Ovarian Cancer. Journal of Clinical Oncology. 26(6). 890–896. 220 indexed citations
9.
Ferrandina, Gabriella, Domenica Lorusso, Sandro Pignata, et al.. (2007). A randomized phase III study of gemcitabine (GEM) versus pegylated liposomal doxorubicin (PLD) in progressive/recurrent ovarian cancer (OC). Journal of Clinical Oncology. 25(18_suppl). LBA5506–LBA5506. 4 indexed citations
10.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Radosław Mądry Breakdown of academic impact, for papers by N. H. Cho Breakdown of academic impact, for papers by Janine Lombard Breakdown of academic impact, for papers by Venkateshwari Ananthapur Breakdown of academic impact, for papers by Katsuya Matsuda Breakdown of academic impact, for papers by Giulia Pomati Breakdown of academic impact, for papers by Ghada E. Esheba Breakdown of academic impact, for papers by Ursula Denison Breakdown of academic impact, for papers by Y. Torii Breakdown of academic impact, for papers by Louisa Mezache
Rankless by CCL
2026